ARWRArrowhead Pharmaceuticals, Inc.
$62.78+105% 1Y
$62.78
$31.6652 weeks$89.61
The financials
Arrowhead Pharmaceuticals, Inc. by the numbers
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $75M in Q3 2026 (quarter ended Jun 30, 2026), up 171% from the same quarter a year earlier. That came with net loss of $194M. For the full year FY2025, revenue was $829M (+23258% year on year) and net income −$1.6M. The next results filing is expected around Nov 24, 2026, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $75M | $28M | +171% |
| Operating income | −$170M | −$166M | n/a |
| Net income | −$194M | −$175M | n/a |
| Diluted EPS | −$1.36 | −$1.26 | n/a |